Puma gains as Roche breast cancer combo disappoints

07:32 EDT 6 Jun 2017 | pharmaphorum

Few would have predicted that little biotech Puma would get the advantage over mighty Roche in the race to develop a new breast cancer drug. But that’s what has happened at this year’s ASCO, as Roche’s expensive combination of Perjeta (per...

Original Article: Puma gains as Roche breast cancer combo disappoints


More From BioPortfolio on "Puma gains as Roche breast cancer combo disappoints"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...